Globalization Accelerates Value Realization of Innovative Drugs

全球化加速创新药价值实现

SHANGHAI

上海

,

，

Aug. 25, 2026

2026年8月25日

/PRNewswire/ -- On August 25,

/美通社/ -- 8月25日，

Fosun Pharma

复星医药

('the Company', stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ('the Reporting Period', or 1H2026), the Company recorded revenue of RMB 20.442 billion, a year-on-year increase of 4.75%, or 7.17% at constant exchange rates. Profit attributable to shareholders of the listed company, net of non-recurring gains and losses, stood at RMB 1.144 billion, up 19.09% year-on-year.

（“公司”，股票代码：600196.SH；02196.HK）公布了其2026年中期业绩。2026年上半年（“报告期”或2026年上半年），公司实现营收人民币204.42亿元，同比增长4.75%，按恒定汇率计算增长7.17%。归属于上市公司股东的扣除非经常性损益后的净利润为人民币11.44亿元，同比增长19.09%。

Profit growth outpaced revenue growth, reflecting sustained improvement in earnings quality. Net cash generated from operating activities reached RMB 2.424 billion, rising 13.59% year-on-year..

利润增速超过收入增速，反映出盈利质量的持续改善。经营活动产生的现金流量净额达到人民币24.24亿元，同比增长13.59%。

Innovation and globalization stand as the dual core engines driving business performance. Revenue from Innovative Drugs hit RMB 4.911 billion, representing a 13.84% year-on-year increase and accounting for 33.21% of pharmaceutical segment revenue, 2.17 percentage points higher than the same period last year.

创新与全球化是驱动业务绩效的两大核心引擎。创新药收入达到人民币49.11亿元，同比增长13.84%，占医药板块收入的33.21%，较去年同期提升2.17个百分点。

Business revenue from regions outside Chinese mainland and other countries totaled RMB 6.379 billion, growing 16.45% year-on-year and making up 31.21% of total revenue, a year-on-year uplift of 3.14 percentage points. The Group's revenue mix continues to improve..

来自中国大陆以外地区及其他国家的业务收入总计为人民币63.79亿元，同比增长16.45%，占总收入的31.21%，同比提升3.14个百分点。集团收入结构持续优化。

Focusing on Core Therapeutic Areas and Accelerating Clinical Translation of Innovative Drugs

聚焦核心治疗领域，加速创新药的临床转化

Guided by clinical-value-driven innovation, Fosun Pharma prioritises three core therapeutic areas: oncology, immunology and inflammation, and neurodegenerative diseases. It also expands into CVRM (cardiovascular, renal and metabolic), anti-infectives, rare diseases and other segments. Leveraging an open-innovation framework that combines in-house R&D, two-way licensing and fund-incubation models, the Company accelerates clinical translation and pushes forward its innovation-led transformation..

在临床价值驱动创新的指引下，复星医药聚焦三大核心治疗领域：肿瘤、免疫与炎症以及神经退行性疾病。同时，公司亦拓展至心血管、肾脏及代谢（CVRM）、抗感染、罕见病等其他细分领域。依托融合自主研发、双向许可引进以及基金孵化模式的开放式创新平台，公司加速临床转化，推动其创新引领的战略转型。

In 1H2026, Fosun Pharma's total R&D investment amounted to RMB 3.247 billion, up 25.66% year-on-year. Among this, R&D investment related to Innovative Drugs accounted for 81.61% of total R&D investment, primarily directed towards pipelines such as HLX43, HLX22, GR1803, FXR0906, as well as next-generation small molecule drugs, radiopharmaceuticals, and other cutting-edge technology platforms..

2026年上半年，复星医药的研发投入总额为人民币32.47亿元，同比增长25.66%。其中，与创新药相关的研发投入占研发总投入的81.61%，主要投向HLX43、HLX22、GR1803、FXR0906等管线，以及下一代小分子药物、放射性药物和其他前沿技术平台。

During the reporting period, Fosun Pharma's Innovative Drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7 Innovative Drugs were approved for launch both domestically and overseas. In solid tumor areas including lung cancer, breast cancer, and gastrointestinal tumors, the Company has established differentiated competitive advantages through multi-product synergy and global commercialization.

报告期内，复星医药的创新药进入密集获批与价值兑现期，共有7款创新药的20项适应症在国内外获批上市。在肺癌、乳腺癌和胃肠道肿瘤等实体瘤领域，公司通过多产品协同和全球化商业化布局，建立了差异化的竞争优势。

Han Li Kang (Rituximab), Han Qu You (trastuzumab), and Akynzeo® continue to maintain leading positions in their respective market segments, consistently contributing stable cash flow..

汉利康（利妥昔单抗）、汉曲优（曲妥珠单抗）以及Akynzeo®继续在其各自的市场细分领域保持领先地位，持续贡献稳定的现金流。

During H1 2026, Han Si Zhuang (Serplulimab) gained approval in China for the perioperative treatment of gastric cancer, filling a global unmet clinical need. In the EU, it obtained three additional first-line approvals for squamous non-small-cell lung cancer, esophageal squamous-cell carcinoma and non-squamous non-small-cell lung cancer.

2026年上半年，汉斯状（斯鲁利单抗）在中国获批用于胃癌的围手术期治疗，填补了全球尚未满足的临床需求。在欧盟，该药额外获得了三项一线治疗批准，分别适用于鳞状非小细胞肺癌、食管鳞状细胞癌和非鳞状非小细胞肺癌。

To date, serplulimab has been launched in approximately 50 countries and regions worldwide and is reimbursed under national health-insurance or public-reimbursement schemes in 12 markets including the United Kingdom, Germany, Italy, Spain and Sweden. Han Bei You (Pertuzumab) received successive marketing approvals in the EU and China.

截至目前，斯鲁利单抗已在全球约50个国家和地区上市，并在包括英国、德国、意大利、西班牙和瑞典在内的12个市场被纳入国家医疗保险或公共报销计划。汉贝尤（帕妥珠单抗）相继在欧盟和中国获得上市批准。

It works in synergy with breast-cancer portfolio assets including Han Qu You, Han Nai Jia and Fu Tuo Ning to drive commercial uptake. Fu Mai Ning (luvometinib tablets) secured a new indication for pediatric and adolescent patients aged two years and older with relapsed/refractory Langerhans-cell histiocytosis (LCH) following systemic therapy, addressing an unmet clinical need in China..

它与包括汉曲优、汉奈佳和福妥宁在内的乳腺癌组合资产协同作用，推动商业化放量。复迈宁（伏美替尼片）获得新适应症，用于治疗经过系统性治疗后复发或难治的朗格汉斯细胞组织细胞增生症（LCH）的两岁及以上儿童和青少年患者，填补了中国在这一领域的未满足临床需求。

With regulatory applications accepted for multiple innovative drugs and international multi-center clinical trials for key pipelines moving forward efficiently, Fosun Pharma continues to fuel its long-term commercial growth.

随着多项创新药的监管申请获得受理，以及关键管线的国际多中心临床试验高效推进，复星医药持续为其长期商业增长注入动力。

- The NDA for SAF-189 (foritinib succinate capsules), an ALK inhibitor for non-small-cell lung cancer, has been accepted by the NMPA.

- 用于非小细胞肺癌的ALK抑制剂SAF-189（福瑞替尼琥珀酸胶囊）的新药上市申请（NDA）已获国家药品监督管理局（NMPA）受理。

- The NDA of Fu Mai Ning for adult patients with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) has been accepted and granted priority review by the NMPA.

- 富马替尼用于治疗伴有症状、不可手术的1型神经纤维瘤病（NF1）相关丛状神经纤维瘤的成人患者的新药上市申请（NDA）已获国家药品监督管理局（NMPA）受理，并被纳入优先审评。

- The NDA for Velinotamig (GR1803), a BCMA × CD3 bispecific antibody for multiple myeloma, has been accepted.

- 针对多发性骨髓瘤的BCMA×CD3双特异性抗体Velinotamig（GR1803）的新药申请已获受理。

Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical efficacy featuring high potency and favorable safety profiles across multiple solid tumors types including non-small-cell lung cancer..

核心在研候选药物HLX43和HLX22正在中国、美国、欧洲、澳大利亚、日本及其他地区开展国际多中心临床试验。作为潜在的同类最优泛肿瘤PD-L1靶向抗体偶联药物（ADC），HLX43已在包括非小细胞肺癌在内的多种实体瘤中展现出良好的初步临床疗效，具有高效力和优异的安全性特征。

In the immunology and inflammation field, the Company strengthened its in-house R&D while continuously enriching its pipeline through BD collaborations, obtaining the rights to develop, manufacture, and commercialize roconkibart (anti-IL-17A monoclonal antibody) in Chinese mainland, Hong Kong SAR, Macau SAR, and Taiwan region.

在免疫学与炎症领域，公司在加强内部研发的同时，通过业务开发（BD）合作持续丰富产品管线，获得了罗康基巴特（抗IL-17A单克隆抗体）在中国大陆、香港特别行政区、澳门特别行政区及台湾地区的开发、生产和商业化权利。

The complement inhibitor FXS6837 for the treatment of IgA nephropathy and other glomerular diseases associated with complement dysregulation initiated Phase 2b clinical trials in Chinese mainland. The DPP1 inhibitor FXS7553 is in Phase 2 clinical stage in Chinese mainland for two indications: non-cystic fibrosis bronchiectasis and COPD..

补体抑制剂FXS6837用于治疗IgA肾病及其他与补体失调相关的肾小球疾病，已在中国大陆启动IIb期临床试验。DPP1抑制剂FXS7553在中国大陆针对非囊性纤维化支气管扩张症和慢性阻塞性肺病（COPD）两个适应症正处于II期临床阶段。

In the neurodegenerative diseases field, the integrated diagnosis and treatment layout continues to strengthen. The post-marketing confirmatory clinical trial for Sodium Oligomannate Capsules in Chinese mainland is progressing steadily; as of July 31, 2026, cumulative enrollment exceeded 1,000 cases, reaching over 50% of the planned enrollment target.

在神经退行性疾病领域，一体化诊疗布局持续强化。甘露特钠胶囊在中国大陆的上市后确证性临床试验稳步推进；截至2026年7月31日，累计入组超过1,000例，达到计划入组目标的50%以上。

HT001, an investigational drug for Parkinson's disease, has initiated Phase 1 clinical trials in Australia. Parallel work is underway on the clinical deployment of magnetic-resonance-guided focused-ultrasound therapy and the R&D of companion diagnostic reagents..

HT001 是一款在研的帕金森病药物，已在澳大利亚启动 I 期临床试验。与此同时，磁共振引导聚焦超声治疗的临床应用以及伴随诊断试剂的研发工作也在同步进行。

Rooted in evidence-based medicine, Fosun Pharma presented three oral abstracts at the 2026 ASCO Annual Meeting, including the Phase 3 study of Fu Mai Ning in adult NF1 patients, the Phase 3 study of serplulimab injection in the perioperative setting for gastric cancer, and the clinical study of HLX43 in non-small cell lung cancer.

复星医药立足循证医学，在2026年美国临床肿瘤学会（ASCO）年会上展示了三项口头摘要，包括福迈宁治疗成人神经纤维瘤病1型（NF1）患者的III期研究、斯鲁利单抗注射液用于胃癌围手术期治疗的III期研究，以及HLX43在非小细胞肺癌中的临床研究。

10 studies were selected for poster presentations at the 2026 ASCO Annual Meeting, including data from two Phase 3 studies of Fu Tuo Ning and a study of HLX43 in nasopharyngeal carcinoma. The Company continues to deliver high-quality clinical outcomes in top-tier global journals such as The Lancet and Nature Medicine, as well as at global industry academic conferences, providing solid academic support for international registration and commercial expansion of its products..

10项研究入选2026年美国临床肿瘤学会（ASCO）年会的海报展示，其中包括复拓宁的两项III期临床研究数据以及HLX43在鼻咽癌中的一项研究。公司持续在《柳叶刀》和《自然·医学》等全球顶级期刊以及全球行业学术会议上发表高质量临床研究成果，为其产品的国际注册和商业拓展提供坚实的学术支持。

Deep Globalization: Global Capabilities Accelerate Value Delivery of Innovation

深度全球化：全球能力加速创新价值交付

Among China's early-movers in global pharmaceutical expansion, Fosun Pharma is evolving from mere product exports toward

在中国全球医药扩张的早期先行者中，复星医药正从单纯的产品出口向

system

系统

-

-

level global deployment

全球部署级别

. It strengthens cross-border capabilities across R&D, regulatory affairs, manufacturing and commercialization to maximize the global value of its innovative assets.

它加强了在研发、监管事务、制造和商业化方面的跨境能力，以最大化其创新资产的全球价值。

In terms of out-licensing,

在对外许可方面，

Shanghai Henlius, a subsidiary of Fosun Pharma, has entered strategic partnerships with Eisai and Abbott for serplulimab. Eisai obtains development, manufacturing and exclusive commercialization rights for Japan and agreed territories. Abbott receives exclusive commercial-license rights covering 42 countries and regions across Asia, the Middle East, Africa and Eastern Europe.

复星医药旗下子公司上海汉斯利普已与卫材和雅培就斯鲁利单抗达成战略合作伙伴关系。卫材获得在日本及约定区域的开发、生产和独家商业化权利。雅培则获得覆盖亚洲、中东、非洲和东欧共42个国家和地区的独家商业许可权。

These collaborations accelerate global roll-out of home-grown innovations for patients worldwide..

这些合作加速了本土创新成果在全球患者中的推广与应用。

In terms of in-licensing,

在授权引进方面，

Fosun Pharma entered into a global exclusive option agreement with AriBio for AR1001, an investigational drug for Alzheimer's disease. Building on the existing rights in China and Southeast Asia, Fosun Pharma is entitled to further expand its right to global core markets including the US, Europe, and Japan, with the Company serving as the marketing authorization holder for the product in the corresponding territories.

复星医药与AriBio就阿尔茨海默病在研药物AR1001达成全球独家选择权协议。在现有中国及东南亚地区权利的基础上，复星医药有权将其权利进一步扩展至包括美国、欧洲和日本在内的全球核心市场，并由公司担任相应区域内的产品上市许可持有人。

The international multi-center Phase 3 clinical trial of AR1001 for the treatment of early Alzheimer's disease has completed the last patient's last visit, with top-line results to be announced within 2026..

AR1001用于治疗早期阿尔茨海默病的国际多中心III期临床试验已完成最后一位受试者的末次访视，主要结果将于2026年内公布。

Drawing on years of global GMP-compliant manufacturing experience, Fosun Pharma presses ahead with its internationalization drive. Its biotech manufacturing site supplies products routinely to global markets including China, Europe, Canada, Latin America, Southeast Asia and India. As of period-end, installed biologic capacity totaled 84,000 liters, of which 48,000 liters are commercially operational..

依托多年符合全球药品生产质量管理规范（GMP）的生产经验，复星医药持续推进其国际化战略。其生物制药生产基地定期向包括中国、欧洲、加拿大、拉丁美洲、东南亚和印度在内的全球市场供应产品。截至报告期末，已安装的生物制品产能总计为84,000升，其中48,000升已投入商业化运营。

Fosun Pharma's subsidiary Gland Pharma, as the first injectable manufacturer in India to receive U.S. FDA approval, possesses one-stop development and manufacturing capabilities for complex dosage forms including vials, lyophilized products, ampoules, and pre-filled syringes. Gland Pharma recently entered into a strategic supply agreement with a global leading pharmaceutical company for 55 SKUs of sterile injectable, further validating its technological expertise and customer stickiness in the high-barrier complex formulation segment.

复星医药旗下子公司Gland Pharma作为印度首家获得美国FDA批准的注射剂制造商，拥有涵盖西林瓶、冻干产品、安瓿瓶和预充式注射器在内的复杂制剂一站式研发与生产能力。Gland Pharma近期与一家全球领先的制药公司就55个品规的无菌注射剂签订了战略供应协议，进一步验证了其在高壁垒复杂制剂领域的技术专长和客户粘性。

This platform also provides Fosun Pharma with a unique strategic resource for its globalization layout, creating a differentiated competitive advantage in the process of going global..

该平台也为复星医药的全球化布局提供了独特的战略资源，在其出海进程中打造差异化竞争优势。

Bolstered by its innovation and globalization strengths, Fosun Pharma keeps elevating its industry standing and has achieved an MSCI ESG rating upgrade to AAA

凭借创新与全球化优势，复星医药不断提升行业地位，并实现MSCI ESG评级上调至AAA级

[1]

[1]

. Domestically, it has ranked among the top 10 of MIIT's

. 在国内，其位列工业和信息化部（MIIT）前十名

China Top 100 Pharmaceutical Enterprises

中国医药企业百强榜

for eight consecutive years. Globally, its innovative-pipeline scale places it within the world's top tier, ranking top 20 in Citeline's

连续八年。在全球范围内，其创新产品管线规模位居世界前列，在Citeline的排名中位列前20名。

Global Top 25 Pipeline Scale Pharmaceutical Companies

全球前25强管线规模制药企业

.

。

'Amidst challenging industry dynamics, Fosun Pharma responded to external uncertainties with strategic focus, achieving steady revenue growth.'

在行业环境充满挑战的背景下，复星医药以战略定力应对外部不确定性，实现了营收的稳步增长。

Chen Yuqing, Chairman of Fosun Pharma,

复星医药董事长陈玉清

said, 'We stay firmly committed to innovation and globalization. Concentrating on oncology, immuno-inflammation and neurodegenerative diseases, we leverage our global footprint and two-way BD synergies to build stronger commercial capabilities. Amid global-expansion opportunities for China's innovative drugs, we take a long-term view and advance resolutely toward high-quality development.'.

表示：“我们坚定不移地致力于创新与全球化。聚焦肿瘤、免疫炎症及神经退行性疾病领域，我们依托全球布局以及双向业务拓展（BD）的协同效应，打造更强大的商业化能力。在中国创新药走向全球的机遇中，我们秉持长远视角，坚定不移地推进高质量发展。”

- END -

- 结束 -

About Fosun Pharma

关于复星医药

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services.

复星医药（股票代码：600196.SH；02196.HK）成立于1994年，是一家创新驱动的全球化制药和医疗健康集团。秉承“让全球家庭更健康”的使命，我们专注于创新药物、医疗技术和诊断产品的研发，并提供医疗健康服务。

Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem..

通过我们的业务合作伙伴国药集团，我们还建立了药品分销网络，构建了全面的医药与健康生态系统。

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases.

复星医药致力于创新与全球化。公司已建立针对未满足医疗需求的全球研发创新体系。我们的战略重点聚焦于肿瘤、免疫与炎症、神经退行性疾病，以及精选的心代谢疾病和罕见病等关键治疗领域。

This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids.

该方法有助于开发高价值的竞争性产品管线及综合医疗健康解决方案。同时，复星医药已巩固其核心技术平台，包括但不限于抗体与抗体偶联药物（ADC）、小分子药物及细胞治疗。此外，我们还积极推进放射性药物和小核酸等前沿治疗方式的发展。

These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia..

这些举措加强了我们的早期创新产品组合，并加速了科学发现向药物开发的转化。我们的创新产品现已在全球90多个国家和地区上市，涵盖中国、美国、欧洲、非洲、印度和东南亚等主要市场。

Looking ahead, guided by the strategy of 'Innovation Driven, Deep Globalization, and AI Embracement', Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health..

展望未来，复星医药将在“创新驱动、深度全球化、拥抱AI”战略的指引下，坚守“关爱生命、持续创新、追求卓越、可持续合作”的核心价值观。我们致力于成为全球领先的医疗健康创新整合者，确保医疗创新的成果惠及全球更多患者，为守护人类健康贡献力量。

For more information about the Group, please visit the company website:

如需了解更多关于本集团的信息，请访问公司网站：

https://www.fosunpharma.com/en/

https://www.fosunpharma.com/en/

[1]

[1]

The use by Fosun Pharma of any MSCI Solutions LLC and related entities ('MSCI') data, and the use of MSCI logos, trademarks, service marks or product names, do not constitute a sponsorship, endorsement, recommendation, or promotion of Fosun Pharma by MSCI. MSCI ESG Ratings are solely the opinion of MSCI Solutions.

复星医药对MSCI Solutions LLC及相关实体（“MSCI”）任何数据的使用，以及对MSCI标志、商标、服务标记或产品名称的使用，均不构成MSCI对复星医药的赞助、认可、推荐或推广。MSCI ESG评级仅代表MSCI Solutions的观点。

MSCI services and data are the property of MSCI or its information providers, are provided 'as-is' and without warranty, and MSCI disclaims all liability, including for any damages..

MSCI 服务及数据归 MSCI 或其信息提供商所有，按“现状”提供且不提供任何担保，MSCI 不承担任何责任，包括对任何损害的责任。

SOURCE Fosun Pharma

来源：复星医药

21

二十一

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示